<DOC>
	<DOC>NCT00204607</DOC>
	<brief_summary>vaccination protocol to induce specific immune responses against melanoma associated antigens by intradermal injections of mRNA coding for the corresponding antigen</brief_summary>
	<brief_title>Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients</brief_title>
	<detailed_description>vaccination protocol to induce specific immune responses against melanoma associated antigens by intradermal injections of mRNA coding for the corresponding antigen. Antigens used are Melan-A, Mage-A1, Mage-A3, Survivin, GP100 and Tyrosinase. GM-CSF is used as an adjuvans. Phase I/II clinical trial to analyse safety and immune respones in stage III/IV melanoma patients.</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>stage III/IV fresh frozen tumortissue age 1875 informed consent given Karnofsky &gt;= 70% systemic glucocorticoids brain metestasis other malignancies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>